How will genetic approaches assist in the management of respiratory diseases?

Current Opinion in Pharmacology

Volumn 9, Issue 3, 2009, Pages 256-261

  Hall, Ian P ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL PEPTIDASE; FENOTEROL; G PROTEIN COUPLED RECEPTOR; ISOPRENALINE; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; STEROID; THIOPURINE METHYLTRANSFERASE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HEREDITY; HUMAN; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

DRUG DELIVERY SYSTEMS; FORECASTING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RESPIRATORY TRACT DISEASES; TREATMENT OUTCOME;

EID: 65949097274     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.03.003     Document Type: Review

References (26)

1. Kerem B., Rommens J.M., Buchanan J.A., Markiewicz D., Cox T.K., Chakravarti A., Buchwald M., and Tsui L.C. Identification of the cystic fibrosis gene: genetic analysis. Science 245 (1989) 1073-1080
2. Davis P.B. Cystic fibrosis since 1938. Am J Respir Crit Care Med 173 (2006) 475-482
3. Gloyn A.L., Pearson E.R., Antcliff J.F., Proks P., Bruining G.J., Slingerland A.S., Howard N., Srinivasan S., Silva J.M., Molnes J., et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350 (2004) 1838-1849
4. Flanagan S.E., Edghill E.L., Gloyn A.L., Ellard S., and Hattersley A.T. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 49 (2006) 1190-1197
5. Van Eerdewegh P., Little R.D., Dupuis J., Del Mastro R.G., Falls K., Simon J., Torrey D., Pandit S., McKenny J., Braunschweiger K., et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 418 (2002) 426-430. This paper describes the first asthma candidate gene to be identified by classical positional cloning approaches. There have been a number of replications of associations seen with this gene, although the functionally important polymorphisms responsible for this effect at this locus remain to be defined.
6. Allen M., Heinzmann A., Noguchi E., Abecasis G., Broxholme J., Ponting C.P., Bhattacharyya S., Tinsley J., Zhang Y., Holt R., et al. Positional cloning of a novel gene influencing asthma from chromosome 2q14. Nat Genet 35 (2003) 258-263
7. Melen E., Bruce S., Doekes G., Kabesch M., Laitinen T., Lauener R., Lindgren C.M., Riedler J., Scheynius A., van Hage-Hamsten M., et al., PARSIFAL Genetics Study Group. Haplotypes of G protein-coupled receptor 154 are associated with childhood allergy and asthma. Am J Respir Crit Care Med 171 (2005) 1089-1095
8. Zhang Y., Leaves N.I., Anderson G.G., Ponting C.P., Broxholme J., Holt R., Edser P., Bhattacharyya S., Dunham A., Adcock I.M., et al. Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma. Nat Genet 34 (2003) 181-186
9. Blakey J., Sayers I., Ring S.R., Strachan D.P., and Hall I.P. Positionally cloned asthma susceptibility gene polymorphisms and disease risk in the British 1958 Birth Cohort. Thorax 64 (2009) 381-387
10. Hersh C.P., Raby B.A., Soto-Quirós M.E., Murphy A.J., Avila L., Lasky-Su J., Sylvia J.S., Klanderman B.J., Lange C., Weiss S.T., and Celedón J.C. Comprehensive testing of positionally cloned asthma genes in two populations. Am J Respir Crit Care Med 176 (2007) 849-857
11. Blakey J., Halapi E., Bjornsdottir U.S., Wheatley A., Kristinsson S., Upmanyu R., Stefansson K., Hakonarson H., and Hall I.P. Contribution of ADAM33 polymorphisms to the population risk of asthma. Thorax 60 (2005) 274-276
12. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 (2007) 661-678. A landmark study in the genetics of human disease, demonstrating that genome wide association (GWA) approaches can be used to identify novel genetic risk factors for disease.
13. Moffatt M.F., Kabesch M., Liang L., Dixon A.L., Strachan D., Heath S., Depner M., von Berg A., Bufe A., Rietschel E., et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448 (2007) 470-473. The first GWA study to be published in the respiratory field demonstrates that the ORMDL3 locus on chromosome 17 harbours an asthma susceptibility gene.
14. Gudbjartsson D.F., Bjornsdottir U.S., Halapi E., Helgadottir A., Sulem P., Jonsdottir G.M., Thorleifsson G., Helgadottir H., Steinthorsdottir V., Stefansson H., et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 41 (2009) 342-347
15. Howard T.D., Koppelman G.H., Xu J., Zheng S.L., Postma D.S., Meyers D.A., and Bleecker E.R. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet 70 (2002) 230-236
16. Personalised medicines: hopes and realities. Policy document 18/05, Royal Society; 2005.
17. Ansari A., Arenas M., Greenfield S.M., Morris D., Lindsay J., Gilshenan K., Smith M., Lewis C., Marinaki A., Duley J., and Sanderson J. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 28 (2008) 973-983
18. ••].
19. ••].
20. ••] provide evidence that in a small number of patients, at least some β2 adrenoceptor agonists can be harmful. In each case, excess mortality was noted in patients on treatment, which could not easily be explained by confounding by disease severity.
21. 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 8 (1993) 334-339
22. Hall I.P., Blakey J.D., Al Balushi K.A., Wheatley A., Sayers I., Pembrey M.E., Ring S.M., McArdle W.L., and Strachan D.P. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet 368 (2006) 771-779
23. Israel E., Drazen J.M., Liggett S.B., Boushey H.A., Cherniack R.M., Chinchilli V.M., Cooper D.M., Fahy J.V., Fish J.E., Ford J.G., et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162 (2000) 75-80
24. Israel E., Chinchilli V.M., Ford J.G., Boushey H.A., Cherniack R., Craig T.J., Deykin A., Fagan J.K., Fahy J.V., Fish J., et al., National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364 (2004) 1505-1512
25. Bleecker E.R., Yancey S.W., Baitinger L.A., Edwards L.D., Klotsman M., Anderson W.H., and Dorinsky P.M. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 118 (2006) 809-816
26. Bleecker E.R., Postma D.S., Lawrance R.M., Meyers D.A., Ambrose H.J., and Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370 (2007) 2118-2125. A large retrospective analysis of RCTs that demonstrates that ADRB2 polymorphisms do not explain lack of response to LABAs.